PAVmed Inc (PAVM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $13.03M
Last updated: Nov 17, 2026 at 11:05 AM ET
PAVmed Inc (PAVM) Financials: Revenue, Profit and Cash Flow
PAVmed reported revenue of $71.00K for the fiscal year ended Dec 31, 2025, down 97.6% from the year before. That year, net income was -$2.47M with a net margin of -3477.5%, operating cash flow was -$5.21M and free cash flow was -$5.24M. The quarter ended Sep 30, 2026 had revenue of $41.00K and net income of -$13.04M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $71.00K | -97.6% | -207.0% | -30712.7% | -3477.5% |
| Dec 2024 | $3.00M | +22.1% | -61.6% | -1485.4% | 949.1% |
| Dec 2023 | $2.45M | +550.4% | -161.8% | -2805.7% | -3232.6% |
| Dec 2022 | $377.00K | -24.6% | -858.6% | -24161.0% | -27384.1% |
| Dec 2021 | $500.00K | N/A | -17.0% | -10878.6% | -11225.2% |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71.00K | $3.00M | $2.45M | $377.00K | $500.00K | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $218.00K | $4.84M | $6.42M | $3.61M | $585.00K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | -$147.00K | -$1.84M | -$3.97M | -$3.24M | -$85.00K | $0 | $0 | $0 | $0 | $0 |
| Research and development | $4.49M | $5.93M | $14.28M | $25.34M | $19.85M | $10.96M | $6.63M | $4.25M | $2.62M | $1.72M |
| Operating income | -$21.81M | -$44.49M | -$68.80M | -$91.09M | -$54.39M | -$23.35M | -$14.29M | -$10.56M | -$8.03M | -$5.65M |
| Net income | -$2.47M | $28.43M | -$79.26M | -$103.24M | -$56.13M | -$35.89M | -$17.27M | -$18.17M | -$9.52M | -$5.65M |
| EBITDA | -$2.31M | -$38.34M | N/A | N/A | -$52.48M | N/A | N/A | N/A | N/A | -$5.65M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41.00K | $33.00K | $22.00K | $52.00K | $5.00K | $6.00K | $8.00K | $10.00K | $996.00K | $979.00K | $1.01M | $1.05M |
| Gross profit | -$117.00K | -$89.00K | -$75.00K | -$34.00K | -$50.00K | -$35.00K | -$28.00K | -$39.00K | -$385.00K | -$687.00K | -$734.00K | -$561.00K |
| Operating income | -$6.73M | -$7.02M | -$8.04M | -$6.80M | -$4.84M | -$4.71M | -$5.45M | -$5.19M | -$11.58M | -$13.68M | -$14.04M | -$16.38M |
| Net income | -$13.04M | -$6.60M | -$1.06M | -$2.76M | -$6.01M | -$12.32M | $18.62M | $1.14M | $60.71M | -$14.91M | -$18.51M | -$17.41M |
Balance Sheet
As of Dec 2025, total debt of $11.10M exceeded cash and equivalents by $9.86M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $38.81M | $30.66M | $33.12M | $53.98M | $86.98M | $19.78M | $7.24M | $8.50M | $1.64M | $870.42K |
| Current assets | $2.26M | $2.16M | $24.50M | $43.93M | $82.64M | $18.94M | $6.55M | $8.46M | $1.62M | $741.17K |
| Cash and equivalents | $1.24M | $1.19M | $19.64M | $39.74M | $77.26M | $17.26M | $6.22M | $8.22M | $1.54M | $585.68K |
| Total liabilities | $16.51M | $37.69M | $57.14M | $43.05M | $7.56M | $20.25M | $11.88M | $10.97M | $4.49M | $1.19M |
| Short-term debt | $11.10M | $29.10M | $44.20M | $33.65M | $0 | $10.36M | $8.14M | $7.90M | $0 | N/A |
| Long-term debt | $0 | N/A | N/A | N/A | N/A | $300.00K | N/A | N/A | $1.94M | $0 |
| Shareholder equity | $33.97M | -$2.50M | -$53.83M | -$9.68M | $61.67M | $1.90M | -$3.82M | -$2.31M | -$2.85M | -$319.07K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $35.21M | $40.21M | $45.42M | $38.81M | $38.07M | $43.89M | $52.82M | $30.66M | $30.55M | $39.41M | $37.25M | $33.12M |
| Total liabilities | $25.08M | $20.91M | $20.43M | $16.51M | $12.28M | $12.47M | $11.89M | $37.69M | $39.94M | $58.05M | $57.83M | $57.14M |
| Cash and equivalents | $3.63M | $3.78M | $6.46M | $1.54M | $3.10M | $4.00M | $2.70M | $1.19M | $765.00K | $25.50M | $25.54M | $19.64M |
| Shareholder equity | $27.45M | $35.05M | $39.52M | $33.97M | $32.52M | $37.53M | $44.99M | -$2.50M | -$4.87M | -$73.94M | -$68.78M | -$53.83M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.21M | -$33.55M | -$52.04M | -$70.98M | -$40.59M | -$21.91M | -$13.36M | -$8.79M | -$6.61M | -$4.45M |
| Capital expenditures | $31.00K | $55.00K | $242.00K | $1.54M | $1.47M | $55.00K | $27.00K | $26.61K | $5.30K | $21.79K |
| Free cash flow | -$5.24M | -$33.61M | -$52.28M | -$72.53M | -$42.06M | -$21.97M | -$13.38M | -$8.81M | -$6.61M | -$4.48M |
| Dividends paid | N/A | N/A | $12.55B | $35.23M | $436.00M | $357.00K | $67.44B | $7.10K | $7.10K | $7.10K |
| Share repurchases | $109.00K | $0 | N/A | N/A | $1.31M | N/A | N/A | $0 | $388.63K | $0 |
| Investing cash flow | -$31.00K | -$16.18M | $758.00K | -$4.74M | -$3.72M | -$55.00K | -$27.00K | -$26.61K | -$5.30K | -$21.79K |
| Financing cash flow | $5.59M | $31.28M | $31.17M | $38.21M | $104.31M | $33.01M | $11.38M | $15.50M | $7.56M | $4.30M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.42M | -$2.66M | -$2.62M | -$1.55M | -$896.00K | -$1.18M | -$1.58M | $94.00K | -$8.88M | -$11.66M | -$13.11M | -$11.87M |
| Capital expenditures | $8.00K | $13.00K | $22.00K | $14.00K | $3.00K | $8.00K | $6.00K | $4.00K | $6.00K | $3.00K | $42.00K | $183.00K |
| Free cash flow | $2.41M | -$2.68M | -$2.64M | -$1.56M | -$899.00K | -$1.19M | -$1.59M | $90.00K | -$8.89M | -$11.66M | -$13.15M | -$12.06M |
Frequently Asked Questions About PAVM
What is PAVmed's annual revenue?
PAVmed reported revenue of $71.00K for the fiscal year ended Dec 31, 2025.
How fast is PAVmed's revenue growing?
Revenue was down 97.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -42.7%.
Is PAVmed profitable?
No. PAVmed reported net income of -$2.47M for the fiscal year ended Dec 31, 2025, with a net margin of -3477.5%.
How much free cash flow does PAVM generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$5.21M minus capital expenditures of $31.00K produced free cash flow of -$5.24M.
How much debt does PAVmed have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $11.10M and cash and equivalents of $1.24M.
PAVM pages: Overview, Earnings, Forecast, Financials, Competitors